During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Hundreds of people with aggressive blood cancer will be offered a groundbreaking one-off personalised therapy that ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...